Eli Lilly and (NYSE:LLY) Issues FY 2021 Earnings Guidance


Share on StockTwits

Eli Lilly and (NYSE:LLY) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided EPS guidance of 7.800-8.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.230. The company issued revenue guidance of $26.60 billion-$27.60 billion, compared to the consensus revenue estimate of $27.69 billion.

LLY opened at $187.04 on Tuesday. Eli Lilly and has a one year low of $129.21 and a one year high of $218.00. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.36 and a quick ratio of 1.06. The company’s 50 day simple moving average is $185.84 and its 200-day simple moving average is $176.06. The stock has a market capitalization of $179.37 billion, a P/E ratio of 30.38, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Monday, April 26th. The company reported $1.87 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.12 by ($0.25). The business had revenue of $6.81 billion during the quarter, compared to analyst estimates of $7.10 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The company’s quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.75 earnings per share. As a group, analysts anticipate that Eli Lilly and will post 7.56 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 10th. Shareholders of record on Friday, May 14th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 1.82%. Eli Lilly and’s dividend payout ratio (DPR) is presently 56.29%.

Several brokerages have recently issued reports on LLY. Cowen increased their price objective on shares of Eli Lilly and from $195.00 to $235.00 and gave the stock an outperform rating in a research report on Friday, February 12th. Truist Securities raised their target price on shares of Eli Lilly and from $215.00 to $225.00 and gave the company a buy rating in a research report on Monday, March 22nd. Mizuho decreased their target price on shares of Eli Lilly and from $228.00 to $216.00 and set a buy rating for the company in a research report on Tuesday. Morgan Stanley decreased their price objective on shares of Eli Lilly and from $217.00 to $207.00 and set an overweight rating for the company in a research report on Tuesday. Finally, Bank of America lifted their price objective on shares of Eli Lilly and from $195.00 to $225.00 and gave the stock a buy rating in a research note on Friday, January 22nd. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $200.75.

In related news, major shareholder Lilly Endowment Inc sold 125,284 shares of Eli Lilly and stock in a transaction on Monday, March 8th. The shares were sold at an average price of $209.69, for a total value of $26,270,801.96. Following the completion of the sale, the insider now owns 110,422,933 shares of the company’s stock, valued at approximately $23,154,584,820.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Donald A. Zakrowski sold 3,000 shares of Eli Lilly and stock in a transaction on Wednesday, April 28th. The shares were sold at an average price of $181.38, for a total transaction of $544,140.00. Following the completion of the sale, the chief accounting officer now directly owns 5,987 shares of the company’s stock, valued at approximately $1,085,922.06. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Article: Golden Cross

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.